

- 1996-98 Cornerstone Physicians Corporation, Irvine, CA
Senior Vice President, Physician Services
Chief Medical Officer
Vice President, Physician Development
- 1995-96 Drs. Brager, Gaber and Associates (Internal Medicine)
- 1977-95 J. Leonard Lichtenfeld MD PA (Primary Care Internal Medicine/Medical Oncology)
- 1977-85 Coordinator, Clinical Cancer Program
Sinai Hospital of Baltimore, Baltimore, MD
- 1975-76 Investigator, Baltimore Cancer Research Center, National Cancer Institute,
National Institutes of Health, Baltimore, MD

ACADEMIC APPOINTMENTS

- 1974-76 Fellow, Baltimore Cancer Research Center
University of Maryland Hospital, Baltimore, MD
- 1976-77 Fellow, Department of Medicine
The Johns Hopkins Hospital, Baltimore, MD
- 1977-86 Assistant Professor of Medicine
University of Maryland School of Medicine, Baltimore, MD
- 1977-02 Instructor, Department of Medicine
The Johns Hopkins University School of Medicine, Baltimore, MD

HOSPITAL AFFILIATIONS

- 2000-02 Emeritus Staff, Sinai Hospital of Baltimore
- 1998-00 Special Consultant, Sinai Hospital of Baltimore
Department of Medicine, Baltimore, MD
- 1977-98 Active Staff, Sinai Hospital of Baltimore
Department of OB/GYN, Baltimore, MD
- 1977-98 Active Staff, Sinai Hospital of Baltimore
Department of Medicine, Baltimore, MD
- 1977-02 Courtesy Staff, Department of Medicine
The Johns Hopkins Hospital, Baltimore, MD
- 1979-95 Courtesy Staff, Department of Medicine
Northwest Hospital Center, Randallstown, MD
- 1982-89 Courtesy Staff, Department of Medicine
Homewood Hospital Center, Baltimore, MD
- 1982-91 Consulting Staff, Department of Medicine
Levindale Hebrew Geriatric Center, Baltimore, MD
- 1995-96 Active Staff, Department of Medicine
St. Joseph Hospital, Towson, MD

1995-96 Active Staff, Department of Medicine
Mercy Hospital, Baltimore, MD

UNIFORMED SERVICE

1972-76 U.S. Public Health Service, BCRC, DCT, NCI

MEMBERSHIPS AND SOCIETIES

Alpha Omega Alpha
American College of Physicians
American Medical Association
American Society of Clinical Oncology
Johns Hopkins Medical Surgical Association
Johns Hopkins University Alumni Association
Medical Association of Georgia

BOARD CERTIFICATION

1972 National Board of Medical Examiners
1977 American Board of Internal Medicine
1977 Medical Oncology

LICENSURE

1975 State of Maryland (inactive)
2003 State of Georgia

EDITORIAL ACTIVITIES

1992-95; 96-06 Editorial Board, Physician's Practice Digest
1993-95; 96- Editorial Advisory Board, Internal Medicine News
1999-2003 Editorial Advisory Board, Medical Crossfire

HONORS & OTHER SPECIAL RECOGNITION

1966-67 Dean's List with Distinction, University of Pennsylvania, Philadelphia, PA
1971 Honors in Internal Medicine
Charles Block Memorial Prize in Medicine
Upjohn Research Award
Hahnemann Medical College, Philadelphia, PA
1983 Fellow, American College of Physicians
1987 Distinguished Internist of the Year (Maryland Society of Internal Medicine)
2005 Laureate Award, American College of Physicians (Georgia Chapter)

2007	Master, American College of Physicians
2011 2013	Presidential Citation, American Academy of Dermatology Association
2011	Special Recognition Award, National Council on Patient Information and Education

OFFICES

American Society of Internal Medicine
Board of Trustees, 1990-97
Secretary-Treasurer, 1993-97
Internal Medicine Center to Advance Research and Education (IMCARE)
Board of Trustees, 1990-97
Secretary-Treasurer, 1993-97
American Society of Internal Medicine Political Action Committee
Board of Trustees, 1993-95
Maryland Society of Internal Medicine
Council 1983-94
Secretary-Treasurer, 1986-88
Vice-President, 1988-90
President, 1990-1992
Past President, 1992-94
Medical Staff, Sinai Hospital of Baltimore
Secretary-Treasurer, 1987
Medical Executive Committee, 1988
Levindale Hebrew Geriatric Center
Board of Directors, 1987-89
Medical and Chirurgical Faculty of Maryland
Board of Trustees, 1995-97
American College of Physicians, Georgia Chapter
Treasurer, 2007-2010

COMMITTEES

Sinai Hospital Medical Staff Committees
Cancer Committee, 1977-85
Budget and Finance Committee, Chairman, 1987
Budget and Finance Committee, Member, 1987-88
Utilization Review Committee, 1987
Quality Assurance Committee, 1987
Medical Records Committee, Chairman, 1990-91
Quality Assurance Committee, 1990-91
Department of Medicine Committee, 1993-96
Medical and Chirurgical Faculty of the State of Maryland
Preventive Medicine & Public Health Committee, 1978-81
Committee on Drugs, 1981-87
Legislative Committee, 1983-89; 1995-96
Chairman, Insurance Subcommittee, 1986-87

Co-Chairman, Legislative Committee, 1987-89
 Chairman, Legislative Committee, 1995-96
 Task Force Against Family Violence, 1993-96
 Focused Professional Education Committee (Ad Hoc), 1994

Chairman, Cancer Registry Advisory Committee, State of Maryland
 1982-91

American Society of Internal Medicine
 Delegate, Annual Meeting, 1986-90
 AIDS Task Force, 1987-88
 Health Insurance Benefits Committee, 1991-94
 Finance Committee (Chairman), 1993-97
 Personnel Committee (Chairman), 1993-97
 Investment Committee, 1993-97
 CPT/RBRVS Refinement Committee, 1994-98
 Computer Services Advisory Committee, 1997

Maryland Cancer Consortium for Data-Based Interventions
 Breast Cancer Detection Committee, 1990
 Cancer Data Subcommittee, 1990
 (State of Maryland Department of Health & Mental Hygiene)

American Medical Association
 RVS Update Committee, 1992-
 Alternate Delegate (ASIM), 1995-97
 Delegate (ASIM), 1997-98
 Delegate (ACP), 1998-

Agency for Health Care Policy Research, Department of Health
 and Human Services, Washington, DC,
 Quality Determinants of Mammography Panel, 1992-94

Health Care Access and Cost Commission, State of Maryland
 Payment System Advisory Committee (Alternate), 1994-96
 Pharmacy Benefit Advisory Committee, 1999-2001

American College of Physician
 Medical Services Committee, 1998-02; 2003-7
 Third Party Relations, Payment and Coding Subcommittee
 (Chairman 1998-02), 1998-2003, 2011-
 Members Insurance Subcommittee, 2007-2009

Georgia Chapter:
 Governor's Advisory Committee, 2004-
 Health and Public Policy Committee, 2004-
 Carrier Advisory Committee representative (Medicare), 2004-2010
 Treasurer, 2007-2010

Medical Mutual Liability Insurance Company, Hunt Valley, MD
 Claims Committee, 2000-01

Medical Association of Georgia
 Third Party Payors Committee, 2004-
 Medical Practice Committee (Chairman), 2006-7
 Delegate (Georgia Chapter, American College of Physicians), 2007-

Aetna

National Physician Advisory Board, 2004-

National Council on Patient Information and Education

Board of Directors, 2004-2011

Board Chair, 2008-2011

iHealth Alliance

Board of Directors, 2005-12

eHealth Initiative

Board of Directors, 2011-

Leadership Council, 2006-

Blueprint Engaging Consumers Committee (co-chair), 2007

Centers for Medicare and Medicaid Services

Medicare Evidence Development and Coverage Advisory Committee (MedCAC), 2007-10

American Society of Clinical Oncology

Health Services Committee, 2007-10

National Accreditation Program for Breast Centers

Board of Directors, 2009-

National Business Group on Health

National Advisory Committee on Employer Services for the Cancer
Continuum of Care 2011-

PUBLICATIONS

1. Lichtenfeld JL: Radiation therapy in the medical curriculum. J Med Educ 47:64-66, 1972.
2. Meadows A, Lichtenfeld JL, Koop CE: Wilm's tumor in three children of a woman with congenital hemihypertrophy. N Engl J Med 291:23, 1974.
3. Desner MR, Lichtenfeld JL, Dennison CL, Kalmbach KO, Mardiney MR, Jr: A new apparatus for BCG scarification. J Natl Cancer Inst 54:47-60, 1975.
4. Drake WP, Schumker M, Pendergrast JW, Davis A, Lichtenfeld JL, Mardiney MR, Jr: The importance of synthetic polynucleotide substrates in the elevation of abnormal nucleolytic activity associated with the sera of cancer patients. J Natl Cancer Inst 55:1055-1059, 1975.
5. Wiernik PH, Schimpff SC, Schiffer CA, Lichtenfeld JL, Aisner J, Fortner C: A randomized clinical comparison of daunorubicin alone with a combination of daunorubicin, cytosine arabinoside, thioguanine, and pyrimethamine for the treatment of acute non-lymphocytic leukemia. Cancer Treat Rep 60:41-53, 1976.

6. Schiffer CA, Lichtenfeld JL, Wiernik PH, Mardiney MR, Jr, Joseph JM: Antibody response in patients with acute non-lymphocytic leukemia. Cancer 37:2177-2182, 1976.
7. Lichtenfeld JL, Kirschner RH, Wiernik PH: Familial Sjögren's syndrome with associated primary salivary gland lymphoma. Am J Med 60:286-292, 1976.
8. Lichtenfeld JL, Wiernik PH: Levamisole in phase I trial. Cancer Treat Rep 60:963-964, 1976 (Letter to the Editor).
9. Wiernik PH, Lichtenfeld JL: Combined modality therapy for localized Hodgkin's disease. A seven year update of an early study. Oncology 32:208-213, 1975.
10. Lichtenfeld JL, Desner MR, Mardiney MR, Jr, Wiernik PH: The modulating effects of levamisole on human lymphocyte responsiveness in vitro. Cancer Treat Rep 60:571-574, 1975.
11. Lichtenfeld JL, Wiernik PH, Mardiney MR, Jr, Zarco RM: Abnormalities of complement and its components in patients with acute leukemia, Hodgkin's disease and sarcoma. Cancer Res 36:3678-3680, 1976.
12. Lichtenfeld JL, Wiernik PH, Shortridge DG: Phase I trial of levamisole in patients with non-resectable bronchogenic carcinoma, in Chirigos MA (ed.): Control of Neoplasia by Modulation of the Immune System. New York, Raven Press, 1977, 135-145.
13. Lichtenfeld JL: Current concepts in the management of malignant melanoma. Am J Med Sci 272:184-195, 1976.
14. Lichtenfeld JL: Malignant melanoma. Med Clin N Amer 61:1013-1025, 1977.
15. Lichtenfeld JL, Desner MR, Wiernik PH, Moore S, Mardiney MR, Jr: Amplification by levamisole of human lymphocyte responsiveness to immunological stimulation in vitro, in Chirigos MA (ed.): Modulation of Host Immune Resistance in the Prevention or Treatment of Induced Neoplasias. Fogarty International Center Proceedings #128. Washington DC, US Government Printing Office, 1977, 17-21.
16. Lichtenfeld JL: Tumor immunology, in Hematology and Oncology. MA Lichtman (ed.): New York, Grune & Stratton, Inc., 1980.
17. Lichtenfeld JL: Skin cancer, in Hematology and Oncology. MA Lichtman (ed.): New York, Grune & Stratton, Inc., 1980.
18. Lichtenfeld JL: Head and neck cancer, in Hematology and Oncology. MA Lichtman (ed.): New York, Grune & Stratton, Inc., 1980.
19. Van Echo DA, Chiuten DF, Gormley PE, Lichtenfeld JL: A Phase I clinical and pharmacological study of m-AMSA (NSC 249992) employing an intermittent every other week schedule. Cancer Res 39:3881-3884, 1979.
20. Van Echo DA, Chiuten DF, Whitacre M, Aisner J, Lichtenfeld JL, Wiernik PH: A Phase I trial of pentamethylmelamine (NSC 118742, PMM) in patients with previously treated malignancies. Cancer Treat Rep 64:1335-1339, 1980.
21. Bohlman ME, Lichtenfeld JL, Goldman SM: Lymph node calcification secondary to chemotherapy for histiocytic lymphoma. Diagnostic Imaging, 50:259-262, 1981.
22. Lichtenfeld JL: State mandated Medicare assignment. Maryland Medical Journal 37:71-74, 1988.
23. Lichtenfeld JL: Book Review: Molecular Foundations of Oncology, Samuel Broder (ed), Maryland Medical Journal 41:657, 1992.

24. Bassett LW, Hendrick RE, Bassford TL et al. Clinical Practice Guideline: Quality Determinants of Mammography. AHCPR Publication No. 95-0632. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, October 1994.
25. Bassett LW, Hendrick RE, Bassford TL et al. High Quality Mammography: Information for Referring Providers. Quick Reference Guide for Clinicians No. 13. AHCPR Publication No. 95-0633. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, October 1994.
26. Lichtenfeld JL: The RBRVS: Fixing the Flaws. The Internist 36:13-16, 1995.
27. Lichtenfeld JL: Comparing Chickens and Patients Like Comparing Apples and Oranges – It's Not the Same Thing at All; Physician's Practice Digest 9(1):39, 1999.
28. Herdman R and Lichtenfeld L: Fulfilling the Potential of Cancer Prevention and Early Detection: An American Cancer Society/Institute of Medicine Symposium; The National Academies Press, Washington, DC (2004)
29. Lichtenfeld JL. Cancer Care and Survivorship Planning: Promises and Challenges. J Oncol Pract 2009 5: 116-118
30. Lichtenfeld JL: Can the Beast be Tamed? The Woeful Tale of Accurate Health Information on the Internet. Ann Surg Oncol 19:701-702, 2012

ABSTRACTS

1. Lichtenfeld JL, Desner MR, Mardiney MR, Jr, Wiernik PH: Amplification of immunologically induced lymphocyte 3H thymidine incorporation by levamisole. Fed Proc 33:790, 1974.
2. Schiffer CA, Lichtenfeld JL, Mardiney MR, Jr: Antibody production in patients with leukemia. Proc Amer Soc Clin Oncol 16:238, 1975.
3. Drake WP, Pendergrast WJ, Jr, Lichtenfeld JL, Schumkler M, Mardiney MR, Jr: Elevated nuclease activity is correlated with the presence of malignancy: the use of synthetic polynucleotide substrates. Proc Amer Assoc Cancer Res 16:132, 1975.
4. Lichtenfeld JL, Wiernik PH, Mardiney MR, Jr: Abnormalities of complement and its components in patients with acute leukemia, Hodgkin's disease and sarcoma. Proc Am Soc Hematol 18:173, 1975.
5. Lichtenfeld JL, Wiernik PH: Phase I trial of levamisole in non-resectable bronchogenic carcinoma. Proc Amer Assoc Cancer Res 17:65, 1976.
6. Chang P, Wiernik PH, Lichtenfeld JL, Schiffer CA: Levamisole (L), cytosine arabinoside (Ara-C), and daunorubicin (DNR) induction therapy of adult acute non-lymphocytic leukemia (ANLL). Proc Amer Soc Clin Oncol 19:370, 1978.
7. Smith FP, MacDonald JS, Wooley PV, Hoth DF, Smythe TA, Lichtenfeld JL, Levin B, Schein PS: Phase II evaluation of FAM, 5-fluorouracil (F), Adriamycin (A) and Mitomycin-C (M), in advanced pancreatic cancer (PC). Proc Amer Soc Clin Oncol 20:415, 1979.
8. Van Echo DA, Gormley P, Lichtenfeld JL, Scoltock M, Wiernik PH: A Phase I study of m-AMSA. Proc Amer Soc Clin Oncol 20:422, 1979.
9. Lichtenfeld JL, Van Echo DA, Aisner J, Wiernik PH: A Phase I trial of pentamethylmelamine (NSC 118742, PMM) in patients with previously treated malignancies. Proc Amer Soc Clin Oncol 21:3407, 1980.

**Committee on Energy and Commerce
U.S. House of Representatives**

Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)

1. Your Name: Dr. J. Leonard Lichtenfeld		
2. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes <input type="checkbox"/>	No <input checked="" type="checkbox"/>
3. Are you testifying on behalf of an entity that is not a government entity?	Yes <input checked="" type="checkbox"/>	No <input type="checkbox"/>
4. Other than yourself, please list which entity or entities you are representing: American Cancer Society, Inc. American Cancer Society Cancer Action Network, Inc.		
5. Please list any Federal grants or contracts (including subgrants or subcontracts) that you or the entity you represent have received on or after October 1, 2011: I have not personally received any federal funds since October 1, 2011. Moreover, I have not been the principal investigator on any grants or contracts awarded to the American Cancer Society, Inc. since October 1, 2011. However, the American Cancer Society, Inc. received approximately \$6.842 million in Federal funds in 2013.		
6. If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity or entities you are representing: I am the Deputy Chief Medical Officer of the American Cancer Society, Inc.		
7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?	Yes <input checked="" type="checkbox"/>	No <input type="checkbox"/>
8. If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2011, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed: Since October 1, 2011, the American Cancer Society, Inc. has not received a Federal grant or contract that exceeded 10 percent of its revenue in the year received. Moreover, since October 1, 2011, the American Cancer Society Cancer Action Network, Inc. has not received a Federal grant or contract that exceeded 10 percent of its revenue in the year received.		
9. Please attach your curriculum vitae to your completed disclosure form. Please see attached.		

Signature: _____



Date: 7/9/14